Cargando…
Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer
BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) is a unique subtype of this disease. Few studies focus on the feasibility of trastuzumab as maintenance or palliative therapy for patients with HER2-positive advanced GC. PATIENTS AND METHODS: We retrospectively...
Autores principales: | Fu, Xiaomin, Zhang, Yong, Yang, Jing, Qi, Yalong, Ming, Yue, Sun, Miaomiao, Shang, Yiman, Yang, Yonghao, Zhu, Xiaoyan, Gao, Quanli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157990/ https://www.ncbi.nlm.nih.gov/pubmed/30275713 http://dx.doi.org/10.2147/OTT.S174138 |
Ejemplares similares
-
Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017) -
Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data
por: Kim, Tae-Hwan, et al.
Publicado: (2021) -
Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma
por: Iqbal, Muhammad Shahid, et al.
Publicado: (2014) -
Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer
por: Shitara, Kohei, et al.
Publicado: (2021) -
Trastuzumab deruxtecan for the treatment of patients with
HER2-positive gastric cancer
por: Kotani, Daisuke, et al.
Publicado: (2021)